What Cyanvac does

CyanVac LLC is a privately held, clinical-stage biotechnology company founded in 2017 and headquartered in Athens, Georgia. The company develops intranasal vaccines built on a proprietary parainfluenza virus 5 (PIV5)-based vector platform invented by CEO Dr. Biao He. The platform is designed to deliver needle-free, single-dose vaccines that generate cellular, humoral, and mucosal immunity, with PIV5 having an established 50+ year safety record from its use in canine distemper vaccines.

Cyanvac's pipeline comprises five programs leveraging this shared backbone: CVXGA (intranasal COVID-19 vaccine, with completed Phase 1 NCT04954287 and Phase 2 NCT05736835 studies); BLB201 (intranasal RSV vaccine expressing native full-length F-protein, granted FDA Fast Track designation and in a Phase 1/2 pediatric trial NCT05655182, developed through wholly-owned affiliate Blue Lake Biotechnology); pandemic avian flu vaccines targeting H5N1 and H7N9; a norovirus candidate; and a Lyme disease candidate. Manufacturing economics are positioned as a differentiator, with the company stating a 300-liter bioreactor can produce millions of doses per month versus the 10,000s of liters required for other virus-based vaccine platforms.

The company is pre-revenue and distributes its candidates only through clinical trials. Commercialization is expected to follow traditional pharmaceutical channels post-approval, with a particular go-to-market emphasis on needle-hesitant populations, pediatric and elderly RSV segments, and government pandemic-procurement pathways. Operations appear to be supported primarily by founder/management capital and academic ties to the University of Georgia, with no disclosed venture or institutional funding rounds.

Name

Cyanvac

Legal name

CyanVac LLC

Website

https://cyanvacllc.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

CyanVac LLC is a privately held, clinical-stage biotechnology company developing needle-free intranasal vaccines on a proprietary PIV5-based vector platform, with a pipeline spanning COVID-19, RSV, avian flu, norovirus, and Lyme disease. It serves clinical trial participants today and targets broad global vaccine markets post-approval.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Vaccines

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)

akta.pro secondary industries

Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral) (HLAAAEAF), Adult Vaccines (HLAIAEAB), Seasonal & Endemic Vaccines (e.g., Influenza) (HLAIAEAD)

Keywords

• Intranasal vaccines
• Vaccine development
• Viral vector platform
• Infectious disease vaccines
• Biopharmaceutical research

Headquarters

HQ city

Athens

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain

Distribution channels2 records

Marketing channels3 records

Core offering

Cyanvac develops intranasal vaccines using a proprietary parainfluenza virus 5 (PIV5)-based vector platform invented by CEO Dr. Biao He. The company's clinical pipeline includes CVXGA (intranasal COVID-19 vaccine with completed Phase 1 and Phase 2 studies), BLB201 (RSV vaccine developed by affiliate Blue Lake Biotechnology with FDA Fast Track designation), and preclinical candidates targeting avian flu (H5N1/H7N9), norovirus, and Lyme disease. All vaccine candidates leverage the PIV5 vector to generate cellular, humoral, and mucosal immunity with needle-free intranasal delivery and scalable manufacturing.

Product overview

CyanVac is developing intranasal vaccines using its proprietary PIV5-based platform technology. The company's pipeline includes CVXGA (intranasal COVID-19 vaccine with completed Phase 1 and Phase 2 studies), BLB201 (RSV vaccine developed by affiliate Blue Lake Biotechnology with FDA Fast Track designation), and preclinical vaccines for pandemic avian flu (H5N1/H7N9), norovirus, and Lyme disease. All vaccines leverage the PIV5 vector system to generate robust cellular, humoral, and mucosal immunity with needle-free intranasal delivery.

Differentiator

Problem solved

Functional benefit

Products and services

• PIV5-Based Vaccine Platform A proprietary parainfluenza virus 5 (PIV5)-based vector system for developing intranasal vaccines that can be easily delivered worldwide. The platform generates robust cellular, humoral, and mucosal immune responses, with potential single-dose efficacy and scalable manufacturing using small bioreactors.
• CVXGA Intranasal COVID-19 vaccine designed to produce mucosal immunity, reduce transmission, address needle hesitancy, and serve as a booster for previously vaccinated or infected individuals. Phase 1 (NCT04954287) and Phase 2 (NCT05736835) studies completed.
• BLB201 Live intranasal RSV vaccine expressing native full-length F-protein, developed by affiliate Blue Lake Biotechnology. Granted FDA Fast Track designation. Phase 1 study completed in adults (NCT05281263); Phase 1/2 study in children in progress (NCT05655182).
• Pandemic (Avian) Flu Vaccines PIV5-based intranasal vaccines protecting against H5N1 and H7N9 avian flu viruses. Designed to generate mucosal immunity that could reduce person-to-person transmission and enable self-administration at home during pandemic scenarios.
• Norovirus Vaccine Vaccine candidate targeting norovirus, the most common cause of acute gastroenteritis worldwide. Addresses approximately 20 million annual US infections, 465,000 ER visits, 190,000 hospitalizations, and 900 deaths.
• Lyme Disease Vaccine Vaccine candidate targeting Lyme disease caused by Borrelia burgdorferi, transmitted by Ixodes ticks. Addresses the most common vector-borne disease in the US with approximately 476,000 annual diagnoses and up to 30% of patients developing post-treatment Lyme disease syndrome.

Quantifiable outcome

• PIV5-based vaccines protect against approximately 15 different pathogens in multiple animal species including mice, guinea pigs, hamsters, ferrets, cats, pigs, and monkeys
• +5 more outcomes

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Blue Lake Biotechnology: CyanVac's wholly-owned affiliate developing the RSV vaccine BLB201 on the same proprietary PIV5-based intranasal platform. It is the closest comparability match — same founder, same technology backbone, same regulatory pathway — but focuses specifically on the BLB201 RSV program while CyanVac holds the broader pipeline.
• Vaxart: Clinical-stage biotech developing needle-free oral tablet vaccine candidates (including COVID and norovirus) using an adenovirus-based vector platform. Direct strategic peer in the "non-injectable respiratory/GI vaccine" niche, with analogous clinical-stage milestones and platform-vs-single-product debate.
• Altimmune: Develops intranasal vaccines (including AdCOVID for COVID-19 and T-COVID for intranasal immune modulation) using an adenovirus-based platform. Direct comparability match on the intranasal vaccine delivery mechanism and respiratory pathogen targets (COVID, RSV, influenza).
• FluGen: Clinical-stage developer of intranasal live-attenuated influenza vaccines (M2SR) targeting improved efficacy over traditional flu shots. Direct intranasal vaccine peer with single-disease focus that overlaps on the mucosal immunity and intranasal delivery thesis.
• Meissa Vaccines: Clinical-stage biotech developing intranasal live-attenuated RSV vaccines (MVs RSV), competing head-to-head with CyanVac-affiliate Blue Lake Biotechnology's BLB201. Direct peer on pediatric RSV intranasal approach with similar small-team, clinical-stage profile.
• Codagenix: Develops intranasal live-attenuated vaccines using codon-deoptimization technology, with preclinical and clinical programs in RSV, influenza, and COVID-19. Direct comparison on the platform-based intranasal vaccine thesis and small-biotech-to-Big-Pharma partnership model.

Emerging players

• CanSino Biologics: Approved an intranasal adenovirus-vectored COVID-19 vaccine (Convidecia Air) and is developing inhaled tuberculosis and other mucosal vaccines. Most commercially advanced intranasal vaccine peer, providing regulatory and manufacturing precedents for the delivery route.
• Bharat Biotech: Developed and markets iNCOVACC, an second-generation intranasal adenoviral COVID-19 vaccine, and is developing intranasal rotavirus, cholera, and typhoid vaccines. Comparable as an intranasal vaccine developer in global public health markets.

Broad incumbents

• MedImmune / AstraZeneca: Inventor and long-time marketer of FluMist, the first commercially successful intranasal influenza vaccine, and a major Big-Pharma vaccine player whose RSV program (nirsevimab via Beyfortus partnership) competes in the same indications as CyanVac. Reference incumbent for intranasal vaccine regulatory pathway and commercial benchmarks.
• Moderna: Dominant mRNA vaccine developer with approved COVID-19 (Spikevax) and RSV (mRESVIA) vaccines plus influenza programs. Incumbent competitor across CyanVac's lead respiratory disease targets, with vastly larger commercial reach but a delivery mechanism that does not generate mucosal immunity.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/cyanvacllc

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cyanvac